RIGL

40.2402.31%
AL

Alison L. Hannah

Member of Scientific Advisory Board

Dr. Alison L. Hannah, M.D. is the Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals, Inc. since July 01, 2026. Dr. Hannah served as Director at Rigel Pharmaceuticals, Inc. from May 2021 and Independent Director until July 1, 2026. Dr. Hannah served as Senior Vice President and Chief Medical Officer at CytomX Therapeutics, Inc. from February 2020 to September 30, 2022. Dr. Hannah served as Chief Medical Officer of Kirilys Therapeutics Inc. Dr. Hannah served as Senior Medical Director at SUGEN. Dr. Hannah began her career at Quintiles. Dr. Hannah served as a Consultant to the pharmaceutical industry since 2000. Dr. Hannah served as Director at NeoGenomics Laboratories, Inc. from June 2015 to May 2026. Dr. Hannah served as an Independent Director at NeoGenomics, Inc. from June 12, 2015 to December 31, 2025. Dr. Hannah has a B.A. in biochemistry and immunology from Harvard University and a medical degree from the University of Saint Andrews.

Positions